cipargamin

Cipargamin is an experimental synthetic antimalarial drug of the spiroindolone class, developed primarily by Novartis and its research partners. It acts as a potent inhibitor of the *Plasmodium falciparum* P-type ATPase 4 (PfATP4), an Na+ efflux transporter on the parasite plasma membrane. Inhibition of PfATP4 leads to osmotic disruption, swelling, and death of blood-stage malaria parasites. Cipargamin demonstrates rapid parasite clearance in clinical trials and has shown efficacy against both *Plasmodium falciparum* and *Plasmodium vivax* malaria, with additional transmission-blocking activity that may help prevent spread to mosquitoes. The drug is being evaluated for both oral and intravenous administration in uncomplicated and severe malaria cases, respectively[2][3][5][6][7].

Other names

cipargaminNITD609NITD-609NITD 609KAE609KAE-609KAE 609